Consideration of sex now required by British Journal of Pharmacology
A new themed issue from British Journal of Pharmacology writes about the importance of sex differences in pharmacology research. A new journal policy recommends that all studies submitted for publication in the journal must consider sex as an experimental variable. Read the themed issue here.
Sex differences in cancer risk and survival
A Swedish thesis have analysed sex differences in cancer risk and survival over time. Women's better survival in non-small cell lung cancer indicates sex differences in tumor biology. Women’s poorer survival in bladder cancer was restricted to those with muscle invasive bladder cancer, indicating differences in clinical management and treatment of men and women with muscle invasive tumors. The thesis also showed that the excess cancer risk in men is explained by body height.
Researchers should have sex and gender in mind
In a special edition of Nature, five experts write that sex and gender are often ignored in research. Thinking about sex and gender would help researchers improve their research, they write. The paper highlights a number of examples where the inclusion of sex and gender has contributed to advanced understanding or insight. The authors specify a roadmap for sex and gender analysis and urge researchers, funding agencies, journals and universities to coordinate efforts to implement robust methods of sex and gender analysis.
The Swedish Research Council introduces sex and gender perspectives in grant applications
Researchers applying for grants from the Swedish Research Council must now describe whether sex and gender perspectives are relevant in their planned research.
Information on more medications are now available
The knowledge bank now contain sex-specific information on several antivirals (ATC code J05), cancer medications (ATC code L01), and medications for endocrine therapy (ATC code L02) .
Sex differences in adverse drug events for antihypertensive agents
A new Swedish study have analyzed sex differences in spontaneous adverse drug events (ADE) for antihypertensives between 2005-2012. In women, a higher prevalence of ADE reports were seen for following pharmacological groups: ACE inhibitors, combination of ACE inhibitor and thiazide, angiotensine II antagonists, combination of angiotensin II antagonist and thiazide, thiazides, and potassium-sparing agents. Aldosteron antagonists was the only pharmacological group with higher prevalence of ADE reports among men.
Coronary artery disease in post-menopausal women
A newly publiced review provides a current perspective on sex differences in coronary artery disease (CAD) and limitations of assessing CAD in post-menopausal women. Novel tools for assessing CAD in post-menopausal women are highlighted.
Sex distribution in drug trials in cariovascular disease examined
The U.S. Food and Drug Administration (FDA) have investigated women's participation in pivotal cardiovascular disease (CVD) trials for drugs receiving FDA approval between 2005-2015. Representation of women was too low i relation to disease prevalence in studies in heart failure, coronary artery disease, and acute coronary syndrome. Representation of men was too low i studies in pulmonell hypertension. No differences between men and women in drug efficacy and safety were observed.
Immunotherapy efficacy differs between men and women
Survival among patients treated with immune checkpoint inhibitors was higher in men than women, according to a large meta-analysis recently published in Lancet Oncology. The meta-analysis included over 11 300 patients treated with ipilimumab, tremelimumab, nivolumab, or pembrolizumab for cancer.
New book examines how drugs affect gender roles
The book Gendering Drugs investigates how drugs help create different beliefs about sex and gender. Expectations and marketing of drugs affect the importance and use of drugs which thus can differ between countries. Topics included are HPV vaccine and treatment of benign prostatic enlargement. The book is written by researchers from, among others, Sweden, Great Britain, Austria and Colombia.
Sex differences in diagnosis and treatment of depression
A new dissertation has examined sex aspects in diagnosing and treating depression in adults, reports the Swedish magazine Läkemedelsvärlden (in Swedish). The thesis shows that more men than women had symptoms of depression, while more women were diagnosed with depression. More women than men were treated with antidepressant drugs.
The sex of animals impact on biomedical research
A recent publication in Nature Communications has quantified the differences between male and female mice. The importance of the sex was greater than previously thought. The findings show that sex should be taken into account when designing and analyzing animal studies, regardless of research field.
Serious adverse events more common in women
The proportion of reports of serious adverse events was higher for women than men in Sweden in 2016, according to the Medical Products Agencys annual report (in Swedish). The number of serious reports for women was highest in the age group 18-64 years, while the corresponding number for men was in the age group 65 years and older. The most common substances in serious reports from healthcare staff were the anticoagulant drugs warfarin, apixaban and rivaroxaban.
Men and women with psoriasis are treated differently
Data from the Stockholm County Council during the period 2001-2016 showed that men with psoriasis recieved more systemic drugs, biological drugs and light therapy than women. Read more in the latest issue of Evidens (in Swedish).
New name - Janusmed Sex & Gender
The knowledge databases and decision support systems by the Stockholm County Council gather under a new name: Janusmed.
Women dispense more melatonin
Dispensed prescriptions of the sleeping hormone melatonin increased during 2016 in Sweden and the largest increase was among adult women, according to new statistics from The Board of Health and Welfare (in Swedish).
Reporting of sex and gender in clinical studies can be improved
Only a minority of scientific clinical studies take sex and gender into account when analyzing and reporting research results. The problem is highlighted in a viewpoint article published in JAMA and in a comment published in Lancet. The articles also suggest guidelines for reporting sex and gender in clinical studies.
Information on 200 substances are now available
The knowledge bank now contain sex-specific information on anti-infective agents, sedatives, and drugs used in alcohol dependece. Also, the first document within the therapeutic area respiratory system has been published (salbutamol), and more are to come. See available substances here.
Release of Sex, Gender and Medical Drugs in English
Here you can find information about sex and gender aspects of different drugs. Almost 200 substances within several therapeutic areas are included so far, and information about more drugs are coming. The English edition has been published for the benefit of interested international colleagues and institutions.
Senast ändrad 2020-06-11
Hitta i sidan